General Catalyst Group Management
EIKN icon

General Catalyst Group Management’s Eikon Therapeutics EIKN Stock Holding History

General Catalyst Group Management’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.98M Hold
305,233
– – 2.11% 6
2026
Q1 		$3.23M Buy
+305,233
New +$4.08M 1.76% 6

Other funds holding EIKN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Foresite Capital Management IV
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Merck & Co
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Foresite Capital Management V
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EcoR1 Capital
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

General Catalyst Group Management's EIKN Position: Q2 2026 in Review

General Catalyst Group Management held its Eikon Therapeutics (EIKN) position steady in Q2 2026 at 305,233 shares worth $3.98M. The position accounts for 2.11% of the portfolio, ranked #6.

General Catalyst Group Management first reported a position in EIKN in Q1 2026 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

  • General Catalyst Group Management held 305,233 shares of Eikon Therapeutics worth $3.98M as of Q2 2026.
  • General Catalyst Group Management left its Eikon Therapeutics share count unchanged in Q2 2026.
  • Eikon Therapeutics made up 2.11% of General Catalyst Group Management's portfolio in Q2 2026, its #6 holding.
  • General Catalyst Group Management first reported a position in Eikon Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on General Catalyst Group Management's 13F filing for Q2 2026, filed 17 Aug 2026.